Biotech Stocks In Spotlight As Vertex Extends Breakout | IBD Live

TL;DR

Vertex and Amgen, along with other biotech companies, are showing strong performance with breakout patterns and holding up well. Vertex has various drugs in their pipeline, including treatments for cystic fibrosis and partnership with CRISPR technology.

Transcript

[Applause] I think I mentioned vertex and Amgen last week you know they were you know both kind of uh on the verge of breaking out um and did break out and both of them look really strong and I mentioned how you know these might be a little bit slower moving um but I mean the these These are working right now the you know very tight action that it ... Read More

Key Insights

• 🎭 Vertex, Amgen, and Regeneron are performing well in the biotech industry with breakout patterns and tight action.
• 🫓 Flat bases are considered attractive patterns in the market.
• ❓ The focus of Vertex on cystic fibrosis and its partnership with CRISPR technology provides promising opportunities.
• 💪 The performance of these companies is supported by a strong pipeline of drugs and established products.
• 🙂 Regeneron experienced a slight pullback but still has potential for an entry point.
• 🏃 Investor caution should be exercised considering upcoming earnings announcements.
• 🍉 These companies have potential for society-changing drugs and may have long-term growth prospects.

Questions & Answers

Q: Which companies in the biotech industry are performing well?

Vertex and Amgen have shown strong performance, with breakout patterns and tight action. Regeneron also had a slight pullback but is still holding up.

Q: What are the specific areas of focus for Vertex?

Vertex is particularly focused on treatments for cystic fibrosis, as well as having a partnership with CRISPR technology for sickle cell anemia and other conditions.

Q: Are these companies considered speculative investments?

While they do have potential, these companies are not as speculative compared to others in the biotech industry. They have established products and a strong pipeline of drugs.

Q: How should investors approach entry points for these stocks?

For conservative investors, it is advisable to wait for a pullback and observe if the stock proves itself. More aggressive investors may consider looking for early entry points on the five-minute chart.

Summary & Key Takeaways

• Vertex and Amgen have breakout patterns and are performing well, with a focus on flat bases.

• These companies have a strong pipeline of drugs and established products.

• Regeneron showed a slight pullback but is still holding up and may present a potential entry point.